{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:02:08Z","timestamp":1792609328380,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    After the Covid-19 pandemic, pertussis has made a spectacular comeback in Europe and many other parts of the world, while during the pandemic it had essentially disappeared because of the social distancing requirements. However, even before the Covid-19 pandemic, the disease was on the rise in many countries, especially those that have replaced whole-cell pertussis vaccines by acellular pertussis vaccines. Several reasons may account for this upsurge, including strain adaptation to escape vaccine-induced immunity, rapid waning of immunity after vaccination and the failure of current vaccines to prevent infection by and transmission of the causative agent\n                    <jats:italic>Bordetella pertussis<\/jats:italic>\n                    . Various strategies have been deployed to control the disease, the most effective of which is maternal vaccination during pregnancy to protect the newborn against the most severe and deadly forms of the disease. However, ultimate control of pertussis likely requires novel vaccines, which prevent infection and transmission, not only disease. One of them is the live attenuated BPZE1 vaccine, which has shown promise in pre-clinical and clinical studies and may therefore perhaps become a gamechanger.\n                  <\/jats:p>","DOI":"10.1038\/s44321-025-00199-2","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:57:10Z","timestamp":1740376630000},"page":"594-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pertussis before, during and after Covid-19"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7295-7336","authenticated-orcid":false,"given":"Camille","family":"Locht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"199_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689394","volume":"12","author":"B Abu-Raya","year":"2021","unstructured":"Abu-Raya B, Maertens K, Munoz FM, Zimmermann P, Curtis N, Halperin SA, Rots N, Barug D, Holder B, Kampmann B et al (2021) The effect of tetanus-diphtheria-acellular-pertussis immunization during pregnancy on infant antibody responses: individual-participant data meta-analysis. Front Immunol 12:689394","journal-title":"Front Immunol"},{"key":"199_CR2","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/s41385-018-0080-x","volume":"11","author":"AC Allen","year":"2018","unstructured":"Allen AC, Wilk MM, Misiak A, Borkner L, Murphy D, Mills KHG (2018) Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells. Mucosal Immunol 11:1763\u20131776","journal-title":"Mucosal Immunol"},{"key":"199_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0382-8","volume":"13","author":"BM Althouse","year":"2015","unstructured":"Althouse BM, Scarpino SV (2015) Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med 13:146","journal-title":"BMC Med"},{"key":"199_CR4","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S0140-6736(14)60686-3","volume":"384","author":"G Amirthalingam","year":"2014","unstructured":"Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, Fry NK, Miller E, Ramsay M (2014) Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 384:1521\u20131528","journal-title":"Lancet"},{"key":"199_CR5","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1126\/science.7063839","volume":"215","author":"RM Anderson","year":"1982","unstructured":"Anderson RM, May RM (1982) Directly transmitted infectious diseases: control by vaccination. Science 215:1053\u20131215","journal-title":"Science"},{"key":"199_CR6","doi-asserted-by":"publisher","first-page":"1700832","DOI":"10.2807\/1560-7917.ES.2019.24.7.1700832","volume":"24","author":"AM Barkoff","year":"2019","unstructured":"Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, Stefanelli P, van Gent M, Berbers G, Vestrheim D et al (2019) Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015. Eur Surveill 24:1700832","journal-title":"Eur Surveill"},{"key":"199_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41385-021-00407-5","volume":"14","author":"L Borkner","year":"2021","unstructured":"Borkner L, Curham LM, Wilk MM, Moran B, Mills KHG (2021) IL-17 mediates protective immunity against nasal infection with Bordetella pertussis by mobilizing neutrophils, especially Siglec-R+ neutrophils. Mucosal Immunol 14:1183\u20131202","journal-title":"Mucosal Immunol"},{"key":"199_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167210","volume":"8","author":"V Dubois","year":"2023","unstructured":"Dubois V, Chatagnon J, Depessemier M, Locht C (2023) Maternal acellular pertussis vaccination in mice impairs cellular immunity to Bordetella pertussis infection in offspring. JCI Insight 8:e167210","journal-title":"JCI Insight"},{"key":"199_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00270-8","volume":"6","author":"V Dubois","year":"2021","unstructured":"Dubois V, Chatagnon J, Thiriard A, Bauderlique-Le Roy H, Debrie AS, Coutte L, Locht C (2021) Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal Bordetella pertussis carriage. NPJ Vaccines 6:6","journal-title":"NPJ Vaccines"},{"key":"199_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701285","volume":"12","author":"V Dubois","year":"2021","unstructured":"Dubois V, Locht C (2021) Mucosal immunization against pertussis: lessons from the past and perspectives. Front Immunol 12:701285","journal-title":"Front Immunol"},{"key":"199_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3389\/fimmu.2019.01344","volume":"10","author":"S Esposito","year":"2019","unstructured":"Esposito S, Stefanelli P, Fry NK, Fedele G, He Q, Paterson P, Tan T, Knuf M, Rodrigo C, Olivier CW et al (2019) Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines. Front Immunol 10:1344","journal-title":"Front Immunol"},{"key":"199_CR12","unstructured":"European Center for Disease Prevention and Control (2024) Increase of pertussis cases in the EU\/EEA, 8 May 2024. Stockholm. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Increase%20in%20pertussis%20cases%20in%20the%20EU-EEA%20-%20May%202024%20FINAL.pdf"},{"key":"199_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/INF.0000000000000486","volume":"34","author":"CM Healy","year":"2015","unstructured":"Healy CM, Rench MA, Wootton SH, Castagnini LA (2015) Evaluation of the impact of a pertussis cocooning progam on infant pertussis infection. Pediatr infect Dis J 34:22\u201326","journal-title":"Pediatr infect Dis J"},{"key":"199_CR14","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S1473-3099(24)00291-3","volume":"24","author":"E Holt","year":"2024","unstructured":"Holt E (2024) Pertussis outbreak in Czech Republic. Lancet Infect Dis 24:e359","journal-title":"Lancet Infect Dis"},{"key":"199_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106222","volume":"89","author":"Y Hu","year":"2024","unstructured":"Hu Y, Shi W, Meng Q, Yuan L, Gao W, Wang L, Yao K (2024) Detection of Bordetella spp. in children with pertussis-like illness from 2028 to 2024 in China. J Infect 89:106222","journal-title":"J Infect"},{"key":"199_CR16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1473-3099(20)30274-7","volume":"10","author":"M Jahnmatz","year":"2020","unstructured":"Jahnmatz M, Richert L, Al-Tawil N, Storsaeter J, Colin C, Bauduin C, Thalen M, Solovay K, Rubin K, Mielcarek N et al (2020) Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. Lancet Infect Dis 10:1290\u20131301","journal-title":"Lancet Infect Dis"},{"key":"199_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/infdis\/jiad332","volume":"229","author":"P Kapil","year":"2024","unstructured":"Kapil P, Wang Y, Zimmerman L, Gaykema M, Merkel TJ (2024) Repeated Bordetella pertussis infections are required to reprogram acellular pertussis vaccine-primed host responses in the baboon model. J Infect Dis 229:376\u2013383","journal-title":"J Infect Dis"},{"key":"199_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0140-6736(22)02644-7","volume":"401","author":"C Keech","year":"2023","unstructured":"Keech C, Miller VE, Rizzardi B, Hoyle C, Pryor MJ, Ferrand J, Solovay K, Thalen M, Noviello S, Goldstein P et al (2023) Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus\u2014diphtheria\u2014acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. Lancet 401:843\u2013855","journal-title":"Lancet"},{"key":"199_CR36","doi-asserted-by":"crossref","unstructured":"Lesne E, Cavell BE, Freire-Martin I, Persaud R, Alexander F, Taylor S, Matheson M, van Els CACM, Gorringe A (2020) Acellular pertussis vaccines induce anti-pertactin bactericidal antibodies which drives the emergence of pertactin-negative strains. Front Microbiol 11:2108","DOI":"10.3389\/fmicb.2020.02108"},{"key":"199_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/infdis\/jix254","volume":"216","author":"C Locht","year":"2017","unstructured":"Locht C, Papin JF, Lecher S, Debrie AS, Thalen M, Solovay K, Rubin K, Mielcarek N (2017) Live attenuated pertussis vaccine BPZE1 protects baboons against Bordetella pertussis disease and infection. J Infect Dis 216:117\u2013124","journal-title":"J Infect Dis"},{"key":"199_CR20","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.4049\/jimmunol.170.3.1504","volume":"170","author":"F Mascart","year":"2003","unstructured":"Mascart F, Verscheure V, Malfroot A, Hainaut M, Pierard D, Temerman S, Peltier A, Debrie AS, Levy J, Del Giudice G et al (2003) Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 170:1504\u20131509","journal-title":"J Immunol"},{"key":"199_CR21","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1093\/infdis\/jiae034","volume":"230","author":"KN McCarthy","year":"2024","unstructured":"McCarthy KN, Hone S, McLoughlin RM, Mills KHG (2024) IL-17 and IFN-gamma-producing respiratory tissue-resident memory CD4 T cells persist for decades in adults immunized as children with whole-cell pertussis vaccines. J Infect Dis 230:e518\u2013e523","journal-title":"J Infect Dis"},{"key":"199_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0020065","volume":"2","author":"N Mielcarek","year":"2006","unstructured":"Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Younes AB, Creusy C, Engle J, Goldmann WE, Locht C (2006) Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2:e65","journal-title":"PLoS Pathog"},{"key":"199_CR23","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1016\/j.vaccine.2017.08.009","volume":"35","author":"A Misiak","year":"2017","unstructured":"Misiak A, Leuzzi R, Allen AC, Galletti B, Baudner BC, D\u2019Oro U, O\u2019Hagan DT, Pizza M, Seubert A, Mills KHG (2017) Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. Vaccine 35:5256\u20135263","journal-title":"Vaccine"},{"key":"199_CR24","doi-asserted-by":"publisher","first-page":"2400160","DOI":"10.2807\/1560-7917.ES.2024.29.14.2400160","volume":"29","author":"AC Nordholm","year":"2024","unstructured":"Nordholm AC, Emborg HA, Norgaard SK, Nygaard U, Ronayne A, Nielsen LB, Soborg B, Andersen PH, Dalby T (2024) Pertussis epidemic in Denmark, August 2023 to February 2024. Eur Surveill 29:2400160","journal-title":"Eur Surveill"},{"key":"199_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-63998-2","volume":"10","author":"RHM Raeven","year":"2020","unstructured":"Raeven RHM, Rockx-Brouwer D, Kanojia G, van der Maas L, Bindels THE, ten Have R, van Riet E, Metz B, Kersten GFA (2020) Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses. Sci Rep 10:7396","journal-title":"Sci Rep"},{"key":"199_CR26","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1128\/iai.61.8.3190-3198.1993","volume":"61","author":"K Redhead","year":"1993","unstructured":"Redhead K, Watkins J, Barnard A, Mills KH (1993) Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 61:3190\u20133198","journal-title":"Infect Immun"},{"key":"199_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00862-20","volume":"6","author":"M Sadarangani","year":"2021","unstructured":"Sadarangani M, Kollmann T, Bjornson G, Heath P, Clarke E, Marchant A, Levy O, Leuridan E, Ulloa-Gutierrez R, Cutland CL et al (2021) The fifth international neonatal and maternal immunization symposium (INMIS 2019): securing protection for the next generation. mSphere 6:e00862-20","journal-title":"mSphere"},{"key":"199_CR28","doi-asserted-by":"publisher","first-page":"E399","DOI":"10.1503\/cmaj.160193","volume":"188","author":"KL Schwartz","year":"2016","unstructured":"Schwartz KL, Kwong JC, Deeks SL, Campitelli MA, Jamieson FB, Marchand-Austin A, Stukel TA, Rosella L, Daneman N, Bolotin S et al (2016) Effectiveness of pertussis vaccination and duration of immunity. CMAJ 188:E399\u2013E406","journal-title":"CMAJ"},{"key":"199_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1001\/jama.2012.6364","volume":"308","author":"SL Sheridan","year":"2012","unstructured":"Sheridan SL, Ware RS, Grimwood K, Lambert SB (2012) Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 308:454\u2013456","journal-title":"JAMA"},{"key":"199_CR30","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/s41385-018-0073-9","volume":"11","author":"L Solans","year":"2018","unstructured":"Solans L, Debrie AS, Borkner L, Aguilo N, Thiriard A, Coutte L, Uranga S, Trottein F, Martin C, Mills KHG et al (2018) IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine. Mucosal Immunol 11:1753\u20131762","journal-title":"Mucosal Immunol"},{"key":"199_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/vaccines8030523","volume":"8","author":"M Thalen","year":"2020","unstructured":"Thalen M, Debrie AS, Coutte L, Raze D, Solovay K, Rubin K, Mielcarek N, Locht C (2020) Manufacture of a stable lyophilized formulation of the live attenuated pertussis vaccine BPZE1. Vaccines 8:523","journal-title":"Vaccines"},{"key":"199_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083449","volume":"9","author":"Thorstensson","year":"2014","unstructured":"Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergstr\u00f6m J, Ljungman M, T\u00f6rner A, Wehlin L, Van Broekhoven A, Bosman F et al (2014) A phase I clinical study of the live attenuated Bordetella pertussis vaccine\u2014BPZE1; a single center, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS ONE 9:e83449","journal-title":"PLoS ONE"},{"key":"199_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/cid\/ciz778","volume":"71","author":"N Wanlapakorn","year":"2020","unstructured":"Wanlapakorn N, Maertens K, Vongpunsawad S, Puenpa J, Tran TMP, Hens N, Van Damme P, Thiriard A, Raze D, Locht C et al (2020) Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clin Infect Dis 71:72\u201380","journal-title":"Clin Infect Dis"},{"key":"199_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1073\/pnas.1314688110","volume":"111","author":"JM Warfel","year":"2014","unstructured":"Warfel JM, Zimmerman LI, Merkel TJ (2014) Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman pimate model. Proc Natl Acad Sci USA 111:787\u2013792","journal-title":"Proc Natl Acad Sci USA"},{"key":"199_CR35","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1097\/01.inf.0000160914.59160.41","volume":"24","author":"AM Wendelboe","year":"2005","unstructured":"Wendelboe AM, Van Rie A, Salmaso S, Englund JA (2005) Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 24:S58\u2013S61","journal-title":"Pediatr Infect Dis J"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00199-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-025-00199-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00199-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:43:40Z","timestamp":1779065020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-025-00199-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,9]]}},"alternative-id":["199"],"URL":"https:\/\/doi.org\/10.1038\/s44321-025-00199-2","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Camille Locht is the co-inventor of BPZE1, and its employer holds a patent folio on the technology, currently licensed to ILiAD Biotechnologies. He also reports consulting fees from, and holds equity in ILiAD Biotechnologies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}